Patient Access to Innovative New Technologies Act of 2025 | ChamberLight
Bills · HR 4441
IN COMMITTEE· 119TH CONGRESS
House BillHR 4441Health
Patient Access to Innovative New Technologies Act of 2025
INTRO JUL 16· LAST ACTION JUL 16
READING
3MIN
COSPONSORS
2
READER REACTIONS0 TOTAL
NO VOTES YET · BE THE FIRST
Introduced only
LEGISLATIVE PROGRESS
STEP 2 / 8
Introduced
In Committee
Reported
Passed House
Passed Senate
Conference
To President
Became Law
WHAT THE BILL DOES
AI-written
This bill matters because it tries to close a common gap in healthcare: the time it takes for new, FDA-approved medical technologies to actually become available to patients through insurance coverage. Currently, even after a device is deemed safe and effective by the FDA, it can take a long time for Medicare to establish payment for it, delaying patient access.
If this bill becomes law, Medicare patients could get crucial new treatments more quickly, potentially leading to better health outcomes or even saving lives for those with conditions that could benefit from these innovations. If it doesn't pass, patients might continue to face longer waits for these advanced devices, and hospitals might be less inclined to adopt them due to reimbursement uncertainties. The bill also specifies that these changes should be "budget neutral," meaning they shouldn't increase overall Medicare spending, which is a key consideration for taxpayers and the stability of the Medicare program.
KEY PROVISIONS
5AI-extracted
PROVISION 01
Allows "breakthrough devices" to get conditional approval for Medicare's New Technology Add-On Payment (NTAP) program, even if their final FDA approval comes after the usual NTAP application deadline.
Speeds up Medicare coverage for innovative medical technologies, making them available to patients sooner.
PROVISION 02
Defines a "breakthrough device" as one that has received expedited development and priority review from the FDA and has been fully approved by the FDA for its intended use.
Clearly specifies which advanced medical devices qualify for this faster Medicare payment process.
PROVISION 03
Requires that the conditional NTAP approval only takes effect if the device receives full FDA approval before July 1st of the fiscal year for which the payment was applied.
Ensures that only devices with full FDA clearance eventually receive the additional Medicare payment, maintaining safety standards.
PROVISION 04
Mandates that the implementation of this new conditional approval process must be "budget neutral," meaning it should not increase overall Medicare spending.
Addresses concerns about potential cost increases to the Medicare program from faster adoption of new, potentially expensive technologies.
PROVISION 05
The bill's provisions apply to breakthrough devices that received final FDA approval on or after July 1, 2023, making it somewhat retroactive.
Ensures that some recently approved breakthrough devices could immediately benefit from this faster Medicare payment process upon the bill's enactment.
Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
This bill matters because it tries to close a common gap in healthcare: the time it takes for new, FDA-approved medical technologies to actually become available to patients through insurance coverage. Currently, even after a device is deemed safe and effective by the FDA, it can take a long time for Medicare to establish payment for it, delaying patient access.
If this bill becomes law, Medicare patients could get crucial new treatments more quickly, potentially leading to better health outcomes or even saving lives for those with conditions that could benefit from these innovations. If it doesn't pass, patients might continue to face longer waits for these advanced devices, and hospitals might be less inclined to adopt them due to reimbursement uncertainties. The bill also specifies that these changes should be "budget neutral," meaning they shouldn't increase overall Medicare spending, which is a key consideration for taxpayers and the stability of the Medicare program.
KEY PROVISIONS
AI-extracted
high
Allows "breakthrough devices" to get conditional approval for Medicare's New Technology Add-On Payment (NTAP) program, even if their final FDA approval comes after the usual NTAP application deadline.
Speeds up Medicare coverage for innovative medical technologies, making them available to patients sooner.
med
Defines a "breakthrough device" as one that has received expedited development and priority review from the FDA and has been fully approved by the FDA for its intended use.
Clearly specifies which advanced medical devices qualify for this faster Medicare payment process.
med
Requires that the conditional NTAP approval only takes effect if the device receives full FDA approval before July 1st of the fiscal year for which the payment was applied.
Ensures that only devices with full FDA clearance eventually receive the additional Medicare payment, maintaining safety standards.
high
Mandates that the implementation of this new conditional approval process must be "budget neutral," meaning it should not increase overall Medicare spending.
Addresses concerns about potential cost increases to the Medicare program from faster adoption of new, potentially expensive technologies.
low
The bill's provisions apply to breakthrough devices that received final FDA approval on or after July 1, 2023, making it somewhat retroactive.
Ensures that some recently approved breakthrough devices could immediately benefit from this faster Medicare payment process upon the bill's enactment.
Before July 1 of the fiscal year for which the applicant applied for new technology add-on payments
Full FDA approval/clearance/authorization for a conditionally approved breakthrough device must be granted by this date for NTAP payment to apply.
On or after July 1, 2023
The effective date for applying this section of the bill to breakthrough devices that are approved, cleared, or authorized by the FDA.
GLOSSARY
AI-written
Medicare
A federal health insurance program for people 65 or older, certain younger people with disabilities, and people with End-Stage Renal Disease.
Breakthrough Device
A medical device that the Food and Drug Administration (FDA) has fast-tracked for review because it offers a significant improvement over existing treatments for life-threatening or irreversibly debilitating diseases.
New Technology Add-On Payment (NTAP) Program
A special program within Medicare that provides additional payments to hospitals for using certain new and costly medical technologies that significantly improve patient care.
Conditional Approval
A temporary or provisional approval that allows a medical device to be covered by Medicare's NTAP program, even if it hasn't met all final requirements by a specific deadline, provided those requirements are met later.
Food and Drug Administration (FDA)
A federal agency responsible for protecting public health by ensuring the safety, effectiveness, and security of human and veterinary drugs, biological products, and medical devices.
Budget Neutral
A requirement that new government spending or policy changes do not increase the total amount of money spent, meaning any new costs must be offset by savings or cuts elsewhere.
ACTION TIMELINE
2 EVENTS
JUL 16, 25
Introduced in House
INTROREFERRAL
JUL 16, 25
Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
A foundational federal law that established the Social Security program and, importantly for this bill, created Medicare and Medicaid, providing for the welfare of Americans.
